Brad Shumel, MD
Regeneron Medical Affairs
Sanofi/Regeneron
Dr. Brad Shumel is a Senior Medical Director at Regeneron where he led Phase 3 studies for the dupilumab atopic dermatitis indication in both adults and children, as well as the Phase 3 study for eosinophilic esophagitis. He recently completed the DISCOVER trial -- a Phase 4 study of dupilumab in skin of color patients with moderate to severe atopic dermatitis.